A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and
safety of tislelizumab combined with Anlotinib as maintenance therapy following tislelizumab
and chemotherapy for treatment naïve extensive stage small cell lung cancer.